- Home
- BMA vs GRFS Comparison
BMA vs GRFS Comparison
Compare BMA & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- GRFS
- Stock Information
- Founded
- BMA 1966
- GRFS 1940
- Country
- BMA Argentina
- GRFS Spain
- Employees
- BMA N/A
- GRFS N/A
- Industry
- BMA Commercial Banks
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- BMA Finance
- GRFS Health Care
- Exchange
- BMA Nasdaq
- GRFS Nasdaq
- Market Cap
- BMA 6.3B
- GRFS 5.1B
- IPO Year
- BMA 2006
- GRFS 2006
- Fundamental
- Price
- BMA $85.20
- GRFS $8.43
- Analyst Decision
- BMA Hold
- GRFS Strong Sell
- Analyst Count
- BMA 3
- GRFS 1
- Target Price
- BMA $50.83
- GRFS N/A
- AVG Volume (30 Days)
- BMA 354.1K
- GRFS 1.2M
- Earning Date
- BMA 03-18-2025
- GRFS 01-01-0001
- Dividend Yield
- BMA 6.22%
- GRFS N/A
- EPS Growth
- BMA N/A
- GRFS 283.33
- EPS
- BMA 0.49
- GRFS 0.24
- Revenue
- BMA $4,455,866,638.00
- GRFS $7,467,006,939.00
- Revenue This Year
- BMA N/A
- GRFS $9.41
- Revenue Next Year
- BMA $5.76
- GRFS $8.53
- P/E Ratio
- BMA $19.75
- GRFS $42.74
- Revenue Growth
- BMA 61.52
- GRFS 9.41
- 52 Week Low
- BMA $38.55
- GRFS $5.68
- 52 Week High
- BMA $118.42
- GRFS $9.96
- Technical
- Relative Strength Index (RSI)
- BMA 43.42
- GRFS 62.54
- Support Level
- BMA $78.38
- GRFS $8.21
- Resistance Level
- BMA $85.98
- GRFS $8.81
- Average True Range (ATR)
- BMA 5.38
- GRFS 0.36
- MACD
- BMA -0.06
- GRFS 0.11
- Stochastic Oscillator
- BMA 38.73
- GRFS 78.77
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.